- Home
- PFX vs AGEN Comparison
PFX vs AGEN Comparison
Compare PFX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFX
- AGEN
- Stock Information
- Founded
- PFX 2010
- AGEN 1994
- Country
- PFX United States
- AGEN United States
- Employees
- PFX N/A
- AGEN N/A
- Industry
- PFX Finance: Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFX Finance
- AGEN Health Care
- Exchange
- PFX Nasdaq
- AGEN Nasdaq
- Market Cap
- PFX 101.2M
- AGEN 105.3M
- IPO Year
- PFX N/A
- AGEN 2000
- Fundamental
- Price
- PFX $49.00
- AGEN $3.43
- Analyst Decision
- PFX
- AGEN Buy
- Analyst Count
- PFX 0
- AGEN 4
- Target Price
- PFX N/A
- AGEN $8.33
- AVG Volume (30 Days)
- PFX 1.8K
- AGEN 802.0K
- Earning Date
- PFX 05-06-2025
- AGEN 05-12-2025
- Dividend Yield
- PFX 2.92%
- AGEN N/A
- EPS Growth
- PFX N/A
- AGEN N/A
- EPS
- PFX 5.09
- AGEN N/A
- Revenue
- PFX $24,036,577.00
- AGEN $99,524,000.00
- Revenue This Year
- PFX $10.51
- AGEN $14.49
- Revenue Next Year
- PFX N/A
- AGEN N/A
- P/E Ratio
- PFX $9.63
- AGEN N/A
- Revenue Growth
- PFX 15.02
- AGEN N/A
- 52 Week Low
- PFX $44.32
- AGEN $1.38
- 52 Week High
- PFX $57.40
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PFX 40.01
- AGEN 55.31
- Support Level
- PFX $48.75
- AGEN $2.95
- Resistance Level
- PFX $51.50
- AGEN $3.90
- Average True Range (ATR)
- PFX 0.78
- AGEN 0.40
- MACD
- PFX -0.00
- AGEN -0.07
- Stochastic Oscillator
- PFX 16.67
- AGEN 43.24
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).